UnitedHealth Group (UNH) has seen some volatility recently, pulling back from around the $400 level into the $380s. But I’m watching this movement closely because the next major catalyst is approaching.
📅 Q3 2026 Earnings: October 13, 2026 — Before Market Open
The bigger picture still looks interesting:
✅ Q2 revenue: $112.0B
✅ Adjusted EPS: $6.38
✅ FY2026 adjusted EPS guidance raised to $19.50–$20.00
✅ Management says the turnaround is gaining traction, particularly in Medicare Advantage
⚠️ Commercial medical costs and the recovery of Optum remain key areas to watch
For me, the recent weakness around the $375–$385 zone looks like an important area to monitor.
If UNH can stabilize above $380 and regain $390–$400, sentiment could improve heading toward the October results. A strong Q3 result together with another positive guidance update could become the next major catalyst.
On the other hand, elevated medical-cost trends remain the biggest risk. If costs disappoint or management becomes more cautious on margins, the stock could remain volatile.
🎯 Levels on my watchlist:
Support: $375–$380
First recovery zone: $390–$400
Above $400: momentum becomes much more interesting heading into earnings.
For me, UNH is now less about chasing the price and more about watching whether the company's 2026 turnaround continues to deliver.
October 13 could be an important checkpoint for UNH.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
